| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Echocardiography, Three-Dimensional | 106 | 2023 | 516 | 14.160 |
Why?
|
| Ventricular Function, Left | 87 | 2023 | 592 | 10.200 |
Why?
|
| Heart Ventricles | 86 | 2023 | 760 | 9.650 |
Why?
|
| Echocardiography | 99 | 2023 | 911 | 9.450 |
Why?
|
| Ventricular Dysfunction, Left | 46 | 2023 | 318 | 8.290 |
Why?
|
| Stroke Volume | 58 | 2023 | 456 | 5.800 |
Why?
|
| Image Interpretation, Computer-Assisted | 49 | 2020 | 663 | 5.170 |
Why?
|
| Heart Diseases | 18 | 2019 | 290 | 4.230 |
Why?
|
| Echocardiography, Doppler | 25 | 2020 | 187 | 3.420 |
Why?
|
| Reproducibility of Results | 102 | 2023 | 2705 | 3.360 |
Why?
|
| Magnetic Resonance Imaging, Cine | 24 | 2023 | 159 | 3.310 |
Why?
|
| Myocardial Contraction | 21 | 2020 | 244 | 3.280 |
Why?
|
| Coronary Angiography | 14 | 2019 | 232 | 3.200 |
Why?
|
| Coronary Circulation | 21 | 2022 | 130 | 3.150 |
Why?
|
| Myocardial Ischemia | 17 | 2020 | 162 | 2.840 |
Why?
|
| Contrast Media | 42 | 2023 | 1078 | 2.630 |
Why?
|
| Magnetic Resonance Imaging | 38 | 2023 | 3362 | 2.510 |
Why?
|
| Ventricular Function, Right | 20 | 2023 | 142 | 2.500 |
Why?
|
| Coronary Stenosis | 7 | 2019 | 39 | 2.440 |
Why?
|
| Predictive Value of Tests | 53 | 2023 | 1673 | 2.440 |
Why?
|
| Myocardial Perfusion Imaging | 13 | 2019 | 47 | 2.330 |
Why?
|
| Image Enhancement | 35 | 2019 | 563 | 2.290 |
Why?
|
| Heart | 15 | 2021 | 539 | 2.160 |
Why?
|
| Heart Atria | 17 | 2023 | 250 | 2.100 |
Why?
|
| Imaging, Three-Dimensional | 14 | 2020 | 579 | 2.030 |
Why?
|
| Male | 196 | 2023 | 40965 | 2.010 |
Why?
|
| Fluorocarbons | 14 | 2019 | 72 | 2.010 |
Why?
|
| Middle Aged | 159 | 2023 | 25028 | 2.000 |
Why?
|
| Sensitivity and Specificity | 57 | 2020 | 1991 | 1.960 |
Why?
|
| Female | 192 | 2023 | 44532 | 1.880 |
Why?
|
| Ventricular Dysfunction, Right | 15 | 2022 | 134 | 1.850 |
Why?
|
| Endocardium | 18 | 2019 | 76 | 1.820 |
Why?
|
| Tomography, X-Ray Computed | 16 | 2020 | 2601 | 1.800 |
Why?
|
| Mitral Valve | 21 | 2022 | 248 | 1.790 |
Why?
|
| Practice Guidelines as Topic | 9 | 2017 | 1036 | 1.760 |
Why?
|
| Image Processing, Computer-Assisted | 30 | 2019 | 1204 | 1.750 |
Why?
|
| Humans | 254 | 2023 | 86643 | 1.740 |
Why?
|
| Coronary Artery Disease | 12 | 2022 | 350 | 1.690 |
Why?
|
| Echocardiography, Doppler, Color | 17 | 2019 | 103 | 1.660 |
Why?
|
| Feasibility Studies | 39 | 2022 | 751 | 1.640 |
Why?
|
| Algorithms | 29 | 2021 | 1830 | 1.560 |
Why?
|
| Observer Variation | 35 | 2023 | 602 | 1.550 |
Why?
|
| Hemodynamics | 13 | 2020 | 710 | 1.530 |
Why?
|
| Diastole | 21 | 2023 | 144 | 1.460 |
Why?
|
| Vasodilator Agents | 15 | 2022 | 152 | 1.450 |
Why?
|
| Prospective Studies | 39 | 2023 | 4213 | 1.450 |
Why?
|
| Echocardiography, Transesophageal | 22 | 2022 | 344 | 1.430 |
Why?
|
| Atrial Function, Left | 10 | 2021 | 46 | 1.380 |
Why?
|
| Aged | 102 | 2023 | 18415 | 1.370 |
Why?
|
| Myocardium | 13 | 2020 | 529 | 1.360 |
Why?
|
| Mitral Valve Insufficiency | 12 | 2022 | 187 | 1.310 |
Why?
|
| Purines | 6 | 2016 | 91 | 1.300 |
Why?
|
| Aortic Valve | 9 | 2023 | 222 | 1.280 |
Why?
|
| Cardiomyopathy, Dilated | 12 | 2012 | 97 | 1.270 |
Why?
|
| Albumins | 8 | 2019 | 133 | 1.230 |
Why?
|
| Elasticity Imaging Techniques | 6 | 2016 | 59 | 1.220 |
Why?
|
| Pyrazoles | 6 | 2016 | 153 | 1.220 |
Why?
|
| Adult | 102 | 2023 | 25648 | 1.190 |
Why?
|
| Computer Systems | 10 | 2012 | 79 | 1.130 |
Why?
|
| Reference Values | 28 | 2023 | 674 | 1.110 |
Why?
|
| Echocardiography, Doppler, Pulsed | 5 | 2019 | 23 | 1.100 |
Why?
|
| Tricuspid Valve Insufficiency | 8 | 2020 | 111 | 1.060 |
Why?
|
| Cardiomyopathies | 7 | 2023 | 240 | 1.050 |
Why?
|
| Myocardial Infarction | 7 | 2020 | 376 | 1.050 |
Why?
|
| Cardiac Volume | 6 | 2017 | 53 | 1.040 |
Why?
|
| Ventricular Remodeling | 6 | 2021 | 96 | 1.010 |
Why?
|
| Pericardial Effusion | 1 | 2023 | 19 | 0.950 |
Why?
|
| Machine Learning | 7 | 2021 | 232 | 0.950 |
Why?
|
| Aortic Valve Stenosis | 8 | 2023 | 131 | 0.930 |
Why?
|
| Ventricular Pressure | 4 | 2023 | 34 | 0.920 |
Why?
|
| Coronary Disease | 12 | 2013 | 261 | 0.910 |
Why?
|
| Computed Tomography Angiography | 4 | 2019 | 131 | 0.900 |
Why?
|
| Amyloidosis | 5 | 2023 | 115 | 0.900 |
Why?
|
| Tricuspid Valve | 8 | 2019 | 96 | 0.880 |
Why?
|
| Hypertension, Pulmonary | 7 | 2016 | 346 | 0.850 |
Why?
|
| Vascular Stiffness | 2 | 2019 | 26 | 0.850 |
Why?
|
| Severity of Illness Index | 24 | 2020 | 1801 | 0.840 |
Why?
|
| Artifacts | 8 | 2021 | 244 | 0.830 |
Why?
|
| Cardiac-Gated Imaging Techniques | 2 | 2012 | 19 | 0.830 |
Why?
|
| Vasodilation | 2 | 2019 | 96 | 0.820 |
Why?
|
| Atrial Function, Right | 4 | 2020 | 12 | 0.820 |
Why?
|
| Tomography, Emission-Computed, Single-Photon | 3 | 2016 | 92 | 0.810 |
Why?
|
| Multidetector Computed Tomography | 4 | 2020 | 54 | 0.810 |
Why?
|
| Perfusion Imaging | 3 | 2015 | 50 | 0.810 |
Why?
|
| Coronary Vessels | 4 | 2018 | 177 | 0.800 |
Why?
|
| Atrial Fibrillation | 2 | 2023 | 288 | 0.790 |
Why?
|
| Chest Pain | 2 | 2018 | 42 | 0.780 |
Why?
|
| Heart Valve Diseases | 6 | 2013 | 109 | 0.750 |
Why?
|
| Prognosis | 19 | 2019 | 3679 | 0.730 |
Why?
|
| Aminobutyrates | 1 | 2019 | 13 | 0.720 |
Why?
|
| Protease Inhibitors | 1 | 2019 | 72 | 0.700 |
Why?
|
| Heart Failure | 8 | 2023 | 1204 | 0.700 |
Why?
|
| Tetrazoles | 1 | 2019 | 50 | 0.700 |
Why?
|
| Systole | 14 | 2020 | 129 | 0.680 |
Why?
|
| Angiotensin II Type 1 Receptor Blockers | 1 | 2019 | 90 | 0.680 |
Why?
|
| Electrocardiography | 12 | 2017 | 478 | 0.660 |
Why?
|
| Ventricular Dysfunction | 3 | 2015 | 28 | 0.660 |
Why?
|
| Software | 12 | 2022 | 654 | 0.660 |
Why?
|
| Retrospective Studies | 31 | 2023 | 8489 | 0.650 |
Why?
|
| Defibrillators, Implantable | 4 | 2023 | 129 | 0.630 |
Why?
|
| Models, Cardiovascular | 7 | 2013 | 98 | 0.620 |
Why?
|
| Dobutamine | 11 | 2011 | 61 | 0.590 |
Why?
|
| Signal Processing, Computer-Assisted | 8 | 2003 | 201 | 0.590 |
Why?
|
| Gadolinium DTPA | 5 | 2020 | 261 | 0.550 |
Why?
|
| Time Factors | 19 | 2019 | 5210 | 0.550 |
Why?
|
| Case-Control Studies | 12 | 2019 | 1805 | 0.540 |
Why?
|
| Papillary Muscles | 2 | 2012 | 17 | 0.530 |
Why?
|
| Arterial Occlusive Diseases | 1 | 2016 | 107 | 0.530 |
Why?
|
| Hypertrophy, Left Ventricular | 7 | 2022 | 73 | 0.520 |
Why?
|
| Heart-Assist Devices | 6 | 2021 | 731 | 0.500 |
Why?
|
| Anemia, Sickle Cell | 2 | 2016 | 131 | 0.490 |
Why?
|
| Cardiovascular Diseases | 5 | 2021 | 827 | 0.490 |
Why?
|
| Clinical Competence | 4 | 2021 | 751 | 0.480 |
Why?
|
| Aorta | 5 | 2021 | 280 | 0.470 |
Why?
|
| Artificial Intelligence | 5 | 2023 | 298 | 0.460 |
Why?
|
| Heart Defects, Congenital | 3 | 2013 | 351 | 0.460 |
Why?
|
| Exercise Test | 6 | 2012 | 164 | 0.430 |
Why?
|
| Echocardiography, Stress | 3 | 2009 | 20 | 0.430 |
Why?
|
| Swine | 9 | 2005 | 555 | 0.420 |
Why?
|
| Organ Size | 7 | 2018 | 364 | 0.420 |
Why?
|
| Radiation Dosage | 2 | 2019 | 227 | 0.410 |
Why?
|
| Ventricular Septum | 1 | 2011 | 11 | 0.410 |
Why?
|
| Sarcoidosis | 3 | 2016 | 71 | 0.400 |
Why?
|
| Chordae Tendineae | 3 | 2015 | 23 | 0.400 |
Why?
|
| Automation | 7 | 2019 | 106 | 0.390 |
Why?
|
| Aged, 80 and over | 29 | 2022 | 6509 | 0.390 |
Why?
|
| Transillumination | 2 | 2021 | 9 | 0.380 |
Why?
|
| Young Adult | 21 | 2022 | 5976 | 0.370 |
Why?
|
| Tachycardia, Ventricular | 2 | 2023 | 115 | 0.360 |
Why?
|
| Atrial Function | 2 | 2007 | 17 | 0.350 |
Why?
|
| Cicatrix | 2 | 2020 | 63 | 0.340 |
Why?
|
| ROC Curve | 8 | 2020 | 752 | 0.340 |
Why?
|
| Inpatients | 2 | 2021 | 297 | 0.320 |
Why?
|
| Radiographic Image Interpretation, Computer-Assisted | 4 | 2019 | 466 | 0.320 |
Why?
|
| Mitral Valve Prolapse | 3 | 2020 | 22 | 0.310 |
Why?
|
| Cardiotonic Agents | 5 | 2011 | 87 | 0.310 |
Why?
|
| Linear Models | 11 | 2020 | 421 | 0.310 |
Why?
|
| Ventricular Function | 2 | 2007 | 53 | 0.310 |
Why?
|
| Workflow | 3 | 2023 | 77 | 0.310 |
Why?
|
| Diagnostic Errors | 1 | 2008 | 160 | 0.300 |
Why?
|
| Fractional Flow Reserve, Myocardial | 2 | 2019 | 4 | 0.300 |
Why?
|
| Movement | 3 | 2006 | 299 | 0.280 |
Why?
|
| Biomechanical Phenomena | 3 | 2019 | 457 | 0.280 |
Why?
|
| In Vitro Techniques | 7 | 2009 | 989 | 0.270 |
Why?
|
| Anatomic Landmarks | 2 | 2016 | 31 | 0.270 |
Why?
|
| Adolescent | 20 | 2022 | 8981 | 0.270 |
Why?
|
| Radiographic Image Enhancement | 1 | 2008 | 462 | 0.270 |
Why?
|
| Heart Rate | 7 | 2019 | 492 | 0.260 |
Why?
|
| Hyperemia | 4 | 2012 | 19 | 0.250 |
Why?
|
| Syncope | 2 | 2021 | 34 | 0.250 |
Why?
|
| Animals | 26 | 2008 | 26582 | 0.250 |
Why?
|
| Chicago | 8 | 2019 | 1379 | 0.250 |
Why?
|
| Gadolinium | 2 | 2023 | 103 | 0.240 |
Why?
|
| Cardiology | 3 | 2021 | 123 | 0.240 |
Why?
|
| Microspheres | 6 | 2003 | 101 | 0.240 |
Why?
|
| Risk Assessment | 8 | 2019 | 2261 | 0.240 |
Why?
|
| Blood Pressure | 6 | 2023 | 1143 | 0.230 |
Why?
|
| Europe | 4 | 2015 | 309 | 0.230 |
Why?
|
| Aging | 5 | 2013 | 691 | 0.230 |
Why?
|
| Aortic Valve Insufficiency | 2 | 2016 | 130 | 0.230 |
Why?
|
| Pulmonary Embolism | 2 | 2016 | 222 | 0.230 |
Why?
|
| Multimodal Imaging | 3 | 2019 | 110 | 0.220 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 2 | 2021 | 878 | 0.220 |
Why?
|
| Rabbits | 5 | 2005 | 636 | 0.220 |
Why?
|
| Forecasting | 4 | 2018 | 304 | 0.220 |
Why?
|
| Color | 6 | 2013 | 81 | 0.210 |
Why?
|
| Immunoglobulin Light-chain Amyloidosis | 1 | 2022 | 14 | 0.210 |
Why?
|
| Healthy Volunteers | 5 | 2022 | 143 | 0.210 |
Why?
|
| Follow-Up Studies | 6 | 2019 | 3640 | 0.200 |
Why?
|
| Atrial Appendage | 1 | 2021 | 26 | 0.200 |
Why?
|
| Elastic Modulus | 4 | 2016 | 36 | 0.200 |
Why?
|
| Cohort Studies | 6 | 2020 | 2767 | 0.200 |
Why?
|
| Magnetic Resonance Angiography | 4 | 2016 | 262 | 0.200 |
Why?
|
| Risk Factors | 8 | 2019 | 5417 | 0.200 |
Why?
|
| Evaluation Studies as Topic | 4 | 2019 | 274 | 0.190 |
Why?
|
| Japan | 2 | 2011 | 307 | 0.190 |
Why?
|
| Virtual Reality | 1 | 2020 | 21 | 0.190 |
Why?
|
| Heart Murmurs | 1 | 2020 | 6 | 0.190 |
Why?
|
| American Heart Association | 1 | 2020 | 92 | 0.190 |
Why?
|
| Point-of-Care Systems | 1 | 2021 | 141 | 0.190 |
Why?
|
| Appointments and Schedules | 1 | 2020 | 53 | 0.180 |
Why?
|
| Valsartan | 1 | 2019 | 20 | 0.180 |
Why?
|
| Neprilysin | 1 | 2019 | 42 | 0.180 |
Why?
|
| Pattern Recognition, Automated | 2 | 2012 | 217 | 0.180 |
Why?
|
| Biphenyl Compounds | 1 | 2019 | 68 | 0.180 |
Why?
|
| Motion | 5 | 2019 | 85 | 0.170 |
Why?
|
| Decision Making | 2 | 2018 | 642 | 0.170 |
Why?
|
| Drug Combinations | 1 | 2019 | 224 | 0.170 |
Why?
|
| Cardiac Surgical Procedures | 4 | 2018 | 462 | 0.170 |
Why?
|
| Disease Models, Animal | 3 | 2002 | 2232 | 0.170 |
Why?
|
| Pulmonary Valve Insufficiency | 1 | 2018 | 12 | 0.170 |
Why?
|
| Pericardium | 2 | 1990 | 65 | 0.160 |
Why?
|
| Rest | 2 | 2016 | 48 | 0.160 |
Why?
|
| Diffusion of Innovation | 1 | 2018 | 71 | 0.160 |
Why?
|
| Aortic Diseases | 2 | 2012 | 100 | 0.160 |
Why?
|
| Tetralogy of Fallot | 1 | 2018 | 44 | 0.160 |
Why?
|
| Age Factors | 8 | 2016 | 1851 | 0.160 |
Why?
|
| Allografts | 1 | 2018 | 172 | 0.150 |
Why?
|
| Hypertension | 3 | 2003 | 1141 | 0.150 |
Why?
|
| Pulmonary Artery | 3 | 2019 | 306 | 0.150 |
Why?
|
| Stress, Physiological | 2 | 2015 | 227 | 0.150 |
Why?
|
| Cardiac Catheterization | 3 | 2017 | 291 | 0.140 |
Why?
|
| Transcatheter Aortic Valve Replacement | 1 | 2017 | 47 | 0.140 |
Why?
|
| Treatment Outcome | 7 | 2019 | 7993 | 0.140 |
Why?
|
| Ultrasonography | 4 | 2014 | 695 | 0.140 |
Why?
|
| Sex Factors | 6 | 2020 | 1054 | 0.140 |
Why?
|
| Infusions, Parenteral | 2 | 2005 | 50 | 0.140 |
Why?
|
| Dogs | 7 | 1993 | 685 | 0.140 |
Why?
|
| Lipoproteins, LDL | 1 | 2015 | 83 | 0.130 |
Why?
|
| Microvessels | 1 | 2015 | 70 | 0.130 |
Why?
|
| Lipoproteins, HDL | 1 | 2015 | 96 | 0.130 |
Why?
|
| Cardiovascular System | 2 | 2011 | 71 | 0.130 |
Why?
|
| Patient Selection | 2 | 2017 | 685 | 0.130 |
Why?
|
| Magnetic Resonance Spectroscopy | 3 | 2023 | 318 | 0.130 |
Why?
|
| Prevalence | 4 | 2022 | 1239 | 0.130 |
Why?
|
| Child, Preschool | 9 | 2013 | 3612 | 0.130 |
Why?
|
| Italy | 3 | 2019 | 106 | 0.120 |
Why?
|
| Analysis of Variance | 2 | 2016 | 912 | 0.120 |
Why?
|
| Veins | 1 | 2014 | 94 | 0.120 |
Why?
|
| Controlled Clinical Trials as Topic | 1 | 2013 | 24 | 0.120 |
Why?
|
| Arrhythmias, Cardiac | 3 | 2023 | 187 | 0.120 |
Why?
|
| Electrodes, Implanted | 1 | 2014 | 171 | 0.120 |
Why?
|
| Sample Size | 1 | 2013 | 130 | 0.110 |
Why?
|
| Electrodes | 1 | 2013 | 78 | 0.110 |
Why?
|
| Pacemaker, Artificial | 1 | 2014 | 87 | 0.110 |
Why?
|
| Emergency Service, Hospital | 1 | 2017 | 484 | 0.110 |
Why?
|
| Equipment Design | 4 | 2020 | 406 | 0.110 |
Why?
|
| Heart Transplantation | 1 | 2018 | 705 | 0.110 |
Why?
|
| Adenosine A2 Receptor Antagonists | 1 | 2012 | 13 | 0.110 |
Why?
|
| Aorta, Thoracic | 2 | 2012 | 165 | 0.110 |
Why?
|
| Radiology | 3 | 2016 | 194 | 0.110 |
Why?
|
| Perfusion | 3 | 2022 | 203 | 0.110 |
Why?
|
| Terminology as Topic | 1 | 2013 | 217 | 0.100 |
Why?
|
| Heart Valve Prosthesis | 2 | 2011 | 93 | 0.100 |
Why?
|
| Infusions, Intravenous | 3 | 2013 | 429 | 0.100 |
Why?
|
| Heart Valves | 1 | 2011 | 13 | 0.100 |
Why?
|
| Registries | 2 | 2016 | 702 | 0.100 |
Why?
|
| Heart Valve Prosthesis Implantation | 2 | 2011 | 166 | 0.100 |
Why?
|
| Manometry | 1 | 2011 | 43 | 0.100 |
Why?
|
| Health Care Costs | 1 | 2013 | 238 | 0.100 |
Why?
|
| Internship and Residency | 1 | 2021 | 1004 | 0.100 |
Why?
|
| Vascular Resistance | 1 | 2011 | 102 | 0.100 |
Why?
|
| Cause of Death | 3 | 2017 | 277 | 0.100 |
Why?
|
| Disease Progression | 4 | 2019 | 1531 | 0.100 |
Why?
|
| Infant | 5 | 2018 | 3046 | 0.100 |
Why?
|
| Societies, Medical | 2 | 2015 | 572 | 0.100 |
Why?
|
| Calcinosis | 1 | 2012 | 224 | 0.100 |
Why?
|
| Radionuclide Imaging | 2 | 2009 | 220 | 0.090 |
Why?
|
| Carotid Arteries | 1 | 2011 | 127 | 0.090 |
Why?
|
| Child | 9 | 2013 | 6927 | 0.090 |
Why?
|
| Stress, Mechanical | 3 | 2016 | 248 | 0.090 |
Why?
|
| Health Status Disparities | 1 | 2012 | 170 | 0.090 |
Why?
|
| Parasympathetic Nervous System | 1 | 1990 | 33 | 0.090 |
Why?
|
| Lidocaine | 1 | 1990 | 63 | 0.090 |
Why?
|
| Models, Statistical | 1 | 2013 | 574 | 0.090 |
Why?
|
| Phantoms, Imaging | 2 | 2010 | 429 | 0.090 |
Why?
|
| Regional Blood Flow | 3 | 2016 | 197 | 0.090 |
Why?
|
| Diagnostic Imaging | 1 | 2013 | 469 | 0.090 |
Why?
|
| United States | 5 | 2015 | 6672 | 0.090 |
Why?
|
| Diagnosis, Differential | 3 | 2013 | 1565 | 0.090 |
Why?
|
| Antihypertensive Agents | 1 | 2013 | 521 | 0.090 |
Why?
|
| Adenosine | 2 | 2016 | 225 | 0.080 |
Why?
|
| Bundle-Branch Block | 1 | 2009 | 48 | 0.080 |
Why?
|
| Blood Flow Velocity | 3 | 2020 | 197 | 0.080 |
Why?
|
| Queensland | 1 | 2008 | 5 | 0.080 |
Why?
|
| Body Surface Area | 1 | 2008 | 36 | 0.080 |
Why?
|
| Heart Septum | 1 | 2008 | 45 | 0.080 |
Why?
|
| Stroke | 1 | 2017 | 965 | 0.080 |
Why?
|
| Cross-Sectional Studies | 3 | 2020 | 1621 | 0.080 |
Why?
|
| Cardiac Output | 2 | 2021 | 156 | 0.080 |
Why?
|
| Guideline Adherence | 1 | 2010 | 223 | 0.080 |
Why?
|
| Preoperative Care | 1 | 2010 | 397 | 0.080 |
Why?
|
| Propanolamines | 2 | 1998 | 36 | 0.080 |
Why?
|
| Computer Simulation | 4 | 2013 | 1078 | 0.080 |
Why?
|
| Cannula | 2 | 2019 | 47 | 0.080 |
Why?
|
| Adrenergic beta-Agonists | 2 | 1998 | 72 | 0.080 |
Why?
|
| Kaplan-Meier Estimate | 3 | 2016 | 860 | 0.080 |
Why?
|
| Illinois | 1 | 2008 | 462 | 0.070 |
Why?
|
| Atropine | 3 | 2000 | 59 | 0.070 |
Why?
|
| Adrenergic beta-Antagonists | 2 | 1998 | 152 | 0.070 |
Why?
|
| Radiography | 1 | 2009 | 813 | 0.070 |
Why?
|
| Biomedical Research | 1 | 2011 | 376 | 0.070 |
Why?
|
| Multivariate Analysis | 3 | 2016 | 999 | 0.070 |
Why?
|
| Mitral Valve Stenosis | 2 | 2003 | 37 | 0.070 |
Why?
|
| Diatrizoate Meglumine | 1 | 2005 | 24 | 0.070 |
Why?
|
| Blood Volume | 1 | 2005 | 51 | 0.070 |
Why?
|
| Reference Standards | 1 | 2006 | 159 | 0.070 |
Why?
|
| Dipyridamole | 1 | 2005 | 14 | 0.070 |
Why?
|
| Age Distribution | 2 | 2009 | 204 | 0.070 |
Why?
|
| Aortic Coarctation | 1 | 2005 | 35 | 0.070 |
Why?
|
| Information Storage and Retrieval | 1 | 2006 | 120 | 0.070 |
Why?
|
| Myocardial Reperfusion | 2 | 2004 | 27 | 0.070 |
Why?
|
| Education, Medical, Continuing | 2 | 2016 | 107 | 0.060 |
Why?
|
| User-Computer Interface | 1 | 2006 | 185 | 0.060 |
Why?
|
| Anthropometry | 1 | 2004 | 74 | 0.060 |
Why?
|
| Cardiac Pacing, Artificial | 1 | 2004 | 87 | 0.060 |
Why?
|
| Acoustics | 3 | 2002 | 51 | 0.060 |
Why?
|
| Survival Analysis | 2 | 2018 | 1538 | 0.060 |
Why?
|
| Fourier Analysis | 3 | 1994 | 125 | 0.060 |
Why?
|
| Biopsy | 2 | 2018 | 1163 | 0.060 |
Why?
|
| Monitoring, Intraoperative | 1 | 2003 | 109 | 0.060 |
Why?
|
| Mathematics | 2 | 1993 | 190 | 0.060 |
Why?
|
| Ultrasonography, Doppler | 1 | 2023 | 80 | 0.060 |
Why?
|
| Proportional Hazards Models | 2 | 2016 | 859 | 0.050 |
Why?
|
| Laboratories | 1 | 2021 | 43 | 0.050 |
Why?
|
| Balloon Occlusion | 1 | 2001 | 27 | 0.050 |
Why?
|
| Biomarkers | 2 | 2021 | 1718 | 0.050 |
Why?
|
| Chi-Square Distribution | 2 | 2012 | 364 | 0.050 |
Why?
|
| Cardiac Imaging Techniques | 1 | 2020 | 25 | 0.050 |
Why?
|
| Sex Distribution | 1 | 2000 | 173 | 0.050 |
Why?
|
| Documentation | 1 | 2021 | 98 | 0.050 |
Why?
|
| Autonomic Nervous System Diseases | 1 | 2000 | 19 | 0.050 |
Why?
|
| Ischemia | 1 | 2022 | 243 | 0.050 |
Why?
|
| Germany | 1 | 2020 | 72 | 0.050 |
Why?
|
| Random Allocation | 1 | 2020 | 332 | 0.050 |
Why?
|
| Dilatation, Pathologic | 1 | 2019 | 54 | 0.040 |
Why?
|
| Atrial Remodeling | 1 | 2019 | 17 | 0.040 |
Why?
|
| Arterial Pressure | 1 | 2019 | 38 | 0.040 |
Why?
|
| Survival Rate | 2 | 2016 | 1863 | 0.040 |
Why?
|
| Physical Examination | 1 | 2020 | 149 | 0.040 |
Why?
|
| Radiation Exposure | 1 | 2019 | 24 | 0.040 |
Why?
|
| Pulmonary Wedge Pressure | 1 | 2019 | 108 | 0.040 |
Why?
|
| Electrophysiology | 2 | 1990 | 401 | 0.040 |
Why?
|
| Cost of Illness | 1 | 2018 | 150 | 0.040 |
Why?
|
| Muscle Contraction | 1 | 2019 | 283 | 0.040 |
Why?
|
| Transplantation, Autologous | 1 | 2018 | 331 | 0.040 |
Why?
|
| Troponin T | 1 | 2017 | 37 | 0.040 |
Why?
|
| Prosthesis Fitting | 1 | 2017 | 16 | 0.040 |
Why?
|
| Longitudinal Studies | 1 | 2021 | 1019 | 0.040 |
Why?
|
| Electronic Health Records | 1 | 2021 | 319 | 0.040 |
Why?
|
| Body Size | 1 | 2017 | 91 | 0.040 |
Why?
|
| Nose | 1 | 1997 | 94 | 0.040 |
Why?
|
| Clinical Decision-Making | 1 | 2019 | 257 | 0.040 |
Why?
|
| Education, Medical, Graduate | 1 | 2021 | 369 | 0.040 |
Why?
|
| Muscarinic Antagonists | 1 | 1997 | 55 | 0.040 |
Why?
|
| Transducers | 2 | 1997 | 41 | 0.040 |
Why?
|
| Equipment Safety | 1 | 2016 | 31 | 0.040 |
Why?
|
| Spectrophotometry, Ultraviolet | 1 | 1996 | 43 | 0.040 |
Why?
|
| Vagus Nerve | 2 | 2000 | 45 | 0.030 |
Why?
|
| Databases, Factual | 1 | 2019 | 814 | 0.030 |
Why?
|
| Physicians | 1 | 2004 | 673 | 0.030 |
Why?
|
| Area Under Curve | 1 | 2016 | 334 | 0.030 |
Why?
|
| Prosthesis Design | 1 | 2017 | 278 | 0.030 |
Why?
|
| Online Systems | 1 | 1995 | 24 | 0.030 |
Why?
|
| Prosthesis Failure | 1 | 2016 | 111 | 0.030 |
Why?
|
| Statistics as Topic | 2 | 2008 | 238 | 0.030 |
Why?
|
| Mice, Transgenic | 1 | 1999 | 1540 | 0.030 |
Why?
|
| Stomach | 1 | 2015 | 108 | 0.030 |
Why?
|
| Cardiac Resynchronization Therapy Devices | 1 | 2014 | 19 | 0.030 |
Why?
|
| Diagnosis, Computer-Assisted | 2 | 1997 | 332 | 0.030 |
Why?
|
| Activity Cycles | 1 | 1994 | 19 | 0.030 |
Why?
|
| Torque | 1 | 2013 | 10 | 0.030 |
Why?
|
| Pilot Projects | 1 | 2016 | 839 | 0.030 |
Why?
|
| Myocardial Revascularization | 1 | 2013 | 31 | 0.030 |
Why?
|
| Signal-To-Noise Ratio | 1 | 2014 | 96 | 0.030 |
Why?
|
| Pheochromocytoma | 1 | 1994 | 49 | 0.030 |
Why?
|
| Familial Primary Pulmonary Hypertension | 1 | 2013 | 60 | 0.030 |
Why?
|
| Cost Savings | 1 | 2013 | 66 | 0.030 |
Why?
|
| Models, Economic | 1 | 2013 | 60 | 0.030 |
Why?
|
| Adrenal Gland Neoplasms | 1 | 1994 | 80 | 0.030 |
Why?
|
| Purinergic P1 Receptor Antagonists | 1 | 2012 | 6 | 0.030 |
Why?
|
| Aminophylline | 1 | 2012 | 14 | 0.030 |
Why?
|
| Chronic Disease | 1 | 2016 | 971 | 0.030 |
Why?
|
| Comorbidity | 1 | 2016 | 943 | 0.030 |
Why?
|
| Natriuretic Peptide, Brain | 1 | 2012 | 56 | 0.030 |
Why?
|
| Elasticity | 1 | 2011 | 94 | 0.030 |
Why?
|
| Calcium | 1 | 1996 | 1156 | 0.030 |
Why?
|
| Recovery of Function | 1 | 2012 | 272 | 0.020 |
Why?
|
| Finite Element Analysis | 1 | 2011 | 74 | 0.020 |
Why?
|
| Drug Therapy, Combination | 1 | 2013 | 894 | 0.020 |
Why?
|
| Cost-Benefit Analysis | 1 | 2013 | 454 | 0.020 |
Why?
|
| Aortography | 1 | 2010 | 63 | 0.020 |
Why?
|
| Research Support as Topic | 1 | 2011 | 80 | 0.020 |
Why?
|
| Isoproterenol | 1 | 1990 | 59 | 0.020 |
Why?
|
| Preoperative Period | 1 | 2010 | 91 | 0.020 |
Why?
|
| Peptide Fragments | 1 | 2012 | 460 | 0.020 |
Why?
|
| Postoperative Period | 1 | 2010 | 303 | 0.020 |
Why?
|
| Electric Countershock | 1 | 2009 | 47 | 0.020 |
Why?
|
| Electric Stimulation | 1 | 1990 | 347 | 0.020 |
Why?
|
| Sus scrofa | 1 | 2008 | 45 | 0.020 |
Why?
|
| Equipment Failure Analysis | 1 | 2008 | 90 | 0.020 |
Why?
|
| Postoperative Complications | 1 | 2018 | 2207 | 0.020 |
Why?
|
| Pulmonary Veins | 1 | 2008 | 72 | 0.020 |
Why?
|
| Hypothermia, Induced | 1 | 1988 | 74 | 0.020 |
Why?
|
| Heart Conduction System | 1 | 1988 | 108 | 0.020 |
Why?
|
| Probability | 1 | 2008 | 355 | 0.020 |
Why?
|
| Critical Care | 2 | 2002 | 370 | 0.020 |
Why?
|
| Perinatology | 1 | 2006 | 14 | 0.020 |
Why?
|
| Ultrasonography, Prenatal | 1 | 2006 | 152 | 0.020 |
Why?
|
| Surgery, Computer-Assisted | 1 | 2006 | 99 | 0.020 |
Why?
|
| Mice | 1 | 1999 | 11352 | 0.020 |
Why?
|
| Catheter Ablation | 1 | 2006 | 233 | 0.020 |
Why?
|
| Injections, Intravenous | 1 | 2004 | 244 | 0.020 |
Why?
|
| Palliative Care | 1 | 2004 | 257 | 0.010 |
Why?
|
| Intensive Care Units | 1 | 2004 | 373 | 0.010 |
Why?
|
| Parasympatholytics | 1 | 2000 | 18 | 0.010 |
Why?
|
| False Positive Reactions | 1 | 2000 | 216 | 0.010 |
Why?
|
| Heart Aneurysm | 1 | 1999 | 22 | 0.010 |
Why?
|
| Cardiac Output, Low | 1 | 1999 | 14 | 0.010 |
Why?
|
| Thorax | 1 | 1999 | 75 | 0.010 |
Why?
|
| Hypertrophy, Right Ventricular | 1 | 1999 | 33 | 0.010 |
Why?
|
| Aneurysm, False | 1 | 1999 | 54 | 0.010 |
Why?
|
| Infant, Newborn | 1 | 2004 | 2379 | 0.010 |
Why?
|
| Sex Characteristics | 1 | 2001 | 319 | 0.010 |
Why?
|
| Nitroprusside | 1 | 1998 | 32 | 0.010 |
Why?
|
| Respiration | 1 | 2000 | 262 | 0.010 |
Why?
|
| Miniaturization | 1 | 1997 | 13 | 0.010 |
Why?
|
| Cardiovascular Physiological Phenomena | 1 | 1997 | 36 | 0.010 |
Why?
|
| Mouth | 1 | 1997 | 48 | 0.010 |
Why?
|
| Surface Properties | 1 | 1997 | 130 | 0.010 |
Why?
|
| Computer Graphics | 1 | 1997 | 100 | 0.010 |
Why?
|
| Conscious Sedation | 1 | 1997 | 64 | 0.010 |
Why?
|
| Wakefulness | 1 | 1997 | 134 | 0.010 |
Why?
|
| Safety | 1 | 1997 | 152 | 0.010 |
Why?
|
| Thrombosis | 1 | 1999 | 296 | 0.010 |
Why?
|
| Monitoring, Physiologic | 1 | 1997 | 268 | 0.010 |
Why?
|
| Diabetes Mellitus, Type 1 | 1 | 2000 | 567 | 0.010 |
Why?
|
| Hypertension, Renovascular | 1 | 1994 | 14 | 0.010 |
Why?
|
| Circadian Rhythm | 1 | 1994 | 303 | 0.010 |
Why?
|
| Microcomputers | 1 | 1988 | 26 | 0.000 |
Why?
|